Gilead Sciences (NASDAQ:GILD) PT Lowered to $75.00

Gilead Sciences (NASDAQ:GILD) had its target price lowered by UBS Group from $81.00 to $75.00 in a research note issued to investors on Wednesday, Benzinga reports. The brokerage currently has a neutral rating on the biopharmaceutical company’s stock.

Several other equities research analysts also recently weighed in on the company. Oppenheimer cut their price target on Gilead Sciences from $115.00 to $105.00 and set an outperform rating on the stock in a report on Monday, February 12th. Royal Bank of Canada cut their target price on Gilead Sciences from $76.00 to $75.00 and set a sector perform rating on the stock in a research report on Wednesday, February 14th. Cantor Fitzgerald dropped their price target on Gilead Sciences from $80.00 to $78.00 and set a neutral rating on the stock in a research report on Wednesday, February 7th. Wells Fargo & Company lowered their target price on shares of Gilead Sciences from $84.00 to $77.00 and set an equal weight rating on the stock in a report on Monday, March 4th. Finally, Mizuho cut their target price on Gilead Sciences from $101.00 to $90.00 and set a buy rating for the company in a research note on Thursday, February 22nd. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Gilead Sciences currently has an average rating of Hold and a consensus price target of $84.71.

Gilead Sciences Stock Down 0.6 %

Shares of NASDAQ:GILD opened at $66.93 on Wednesday. The firm has a market capitalization of $83.33 billion, a PE ratio of 14.87, a price-to-earnings-growth ratio of 0.92 and a beta of 0.19. Gilead Sciences has a 1 year low of $66.89 and a 1 year high of $87.86. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.43 and a quick ratio of 1.27. The firm’s 50-day moving average is $72.25 and its two-hundred day moving average is $76.66.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share for the quarter, missing analysts’ consensus estimates of $1.76 by ($0.04). Gilead Sciences had a net margin of 20.89% and a return on equity of 38.85%. The business had revenue of $7.12 billion during the quarter, compared to analyst estimates of $7.10 billion. During the same quarter last year, the firm posted $1.67 EPS. The company’s revenue for the quarter was down 3.7% on a year-over-year basis. Analysts predict that Gilead Sciences will post 6.55 EPS for the current year.

Gilead Sciences Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 28th. Stockholders of record on Friday, March 15th were paid a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.60%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.75. The ex-dividend date of this dividend was Thursday, March 14th. Gilead Sciences’s dividend payout ratio (DPR) is 68.44%.

Insider Buying and Selling at Gilead Sciences

In other news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $73.18, for a total transaction of $146,360.00. Following the completion of the transaction, the insider now owns 100,936 shares of the company’s stock, valued at approximately $7,386,496.48. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 0.16% of the stock is owned by insiders.

Institutional Investors Weigh In On Gilead Sciences

A number of institutional investors have recently added to or reduced their stakes in GILD. Altshuler Shaham Ltd increased its holdings in Gilead Sciences by 7.0% in the 4th quarter. Altshuler Shaham Ltd now owns 1,856 shares of the biopharmaceutical company’s stock valued at $159,000 after purchasing an additional 121 shares in the last quarter. Nilsine Partners LLC boosted its holdings in Gilead Sciences by 1.1% in the 3rd quarter. Nilsine Partners LLC now owns 11,894 shares of the biopharmaceutical company’s stock worth $891,000 after acquiring an additional 127 shares during the period. Etesian Wealth Advisors Inc. grew its holdings in Gilead Sciences by 0.7% during the 4th quarter. Etesian Wealth Advisors Inc. now owns 18,318 shares of the biopharmaceutical company’s stock valued at $1,486,000 after purchasing an additional 128 shares in the last quarter. Financial Counselors Inc. lifted its holdings in Gilead Sciences by 1.5% in the 4th quarter. Financial Counselors Inc. now owns 8,862 shares of the biopharmaceutical company’s stock worth $718,000 after buying an additional 128 shares in the last quarter. Finally, Revolve Wealth Partners LLC grew its stake in shares of Gilead Sciences by 3.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 3,607 shares of the biopharmaceutical company’s stock valued at $292,000 after acquiring an additional 130 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.